Mark Purcell
Stock Analyst at Morgan Stanley
(1.35)
# 3,556
Out of 4,984 analysts
6
Total ratings
66.67%
Success rate
-6.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Upgrades: Overweight | $56 → $58 | $46.86 | +23.77% | 2 | Sep 8, 2025 | |
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $122.78 | -7.15% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $40.05 | +9.86% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $77.56 | +9.59% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $57.20 | +109.79% | 1 | Jan 23, 2024 |
Sanofi
Sep 8, 2025
Upgrades: Overweight
Price Target: $56 → $58
Current: $46.86
Upside: +23.77%
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $122.78
Upside: -7.15%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $40.05
Upside: +9.86%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $77.56
Upside: +9.59%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $57.20
Upside: +109.79%